THE COST-EFFECTIVENESS OF SEQUENTIAL USE OF ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Taylor MJ1, Conway P2, Lebmeier M3, Ganderton M1
1University of York, York, UK, 2Wyeth Europa, Berkshire, UK, 3Wyeth Pharmaceuticals, Maidenhead, UK

OBJECTIVES: Previous studies have established that etanercept is cost-effective when used for the treatment of rheumatoid arthritis (RA) following the failure of 2 DMARD therapies. This analysis explores the use of etanercept after the failure of a previous anti-tumor necrosis factor (anti-TNF) agent.

METHODS: A sequential Markov model was developed to predict the costs and health outcomes associated with different treatments for patients with RA in the UK. The model estimated the cost-effectiveness of sequential anti-TNF therapies when compared against a sequence containing no anti-TNF treatments (i.e. solely DMARD therapies). In a separate analysis, etanercept was compared against rituximab after the failure of a previous anti-TNF. For each treatment, the initial, medium-term and long-term effects on the Health Assessment Questionnaire (HAQ) score were calculated. HAQ scores at each time period determined each patient's utility (QALYs), resource use and mortality. Effectiveness data (HAQ progression, serious adverse events and mortality) were derived from the results of trials and published literature. Various scenarios were assessed using different interpretations of effectiveness data for sequential use of anti-TNFs. Utility scores were converted from HAQ data using the EQ-5D. Cost data were drawn from established national databases.

RESULTS: Patients who received two successive anti-TNF therapies gained between 0.63 (when the initial HAQ change for etanercept was assumed to be 0.51) and 0.76 (when the initial HAQ change was assumed to be 0.40) additional QALYs compared to the DMARD-only cohort. The incremental cost varied between £11,300 and £13,600, resulting in the incremental cost-effectiveness ratio (ICER) ranging between £17,916 and £20,479. When etanercept was compared against rituximab after the failure of a previous anti-TNF agent, the ICER ranged between £27,587/QALY.

CONCLUSIONS: This study demonstrated that etanercept is a cost-effective treatment option for patients with rheumatoid arthritis, even when it is used sequentially with other anti-TNF agents.

COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARSED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND

Piskos R1, Krzysztek J1, Rys P1, Russel-Szymczyk M2, Szkultecka-Debek M2, Szamatoluska K1
1HTA Consulting, Krakow, Poland, 2Roche Polska, Warsaw, Poland

OBJECTIVES: To evaluate the cost-effectiveness of rituximab compared with TNF inhibitors for the treatment of RA patients in the Polish setting.

METHODS: A cost-utility approach was adopted, evaluating the total direct National Health Fund costs and QALYs. Baseline patient characteristics were based on the REFLEX and DANCER phase III trials. A micro-simulation model of 50,000 RA patients estimated lifetime Health Assessment Questionnaire (HAQ) progression, QALYs and direct costs. The starting time-point of the model was the failure of two previous DMARDs. Two treatment options were compared. Upon treatment failure it was assumed patients would follow an identical lifetime treatment strategy consisting of: TRDM—infliximab, rituximab, leflunomide and palliative care or TTD.

—infliximab, etanercept, leflunomide and palliative care. Rituximab was assumed to be administered every 9 months to responding patients. ACR response rates were taken from the phase III RCTs and adjusted for placebo response. The initial HAQ drop by ACR category and longterm HAQ progression were taken from the published literature. RESULTS: Annual drug acquisition and administration costs were lower for TRDM compared to TTD. Discounted total lifetime direct NHF costs were 216,460 pln and 233,734 pln for TRDM and TTD respectively. Total QALYs were 29,952 and 25,854 for TRDM and TTD, respectively. TRDM is a dominant therapy over TTD. CONCLUSIONS: Our model predicted that TRDM dominated options for RA patients who have failed DMARD therapy, with higher estimated QALYs and lower NHF costs. The results will be different when different TNF inhibitors will be taken into account.